{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:24:13Z","timestamp":1763036653002},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiologe"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00117-011-2211-1","type":"journal-article","created":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T07:53:02Z","timestamp":1326700382000},"page":"44-55","source":"Crossref","is-referenced-by-count":6,"title":["Transvaskul\u00e4re Ablation des hepatozellul\u00e4ren Karzinoms"],"prefix":"10.1007","volume":"52","author":[{"given":"B.A.","family":"Radeleff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Stampfl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Bellemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ganten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ehehalt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.U.","family":"Kauczor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,18]]},"reference":[{"key":"2211_CR1","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907\u20131917","journal-title":"Lancet"},{"key":"2211_CR2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","volume":"30","author":"Marelli","year":"2007","unstructured":"Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6\u201325","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2211_CR3","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734\u20131739","journal-title":"Lancet"},{"key":"2211_CR4","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164\u20131171","journal-title":"Hepatology"},{"key":"2211_CR5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00270-009-9752-y","volume":"33","author":"Bonomo","year":"2010","unstructured":"Bonomo G, Pedicini V, Monfardini L et al (2010) Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol 33:552\u2013559","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2211_CR6","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1158\/1078-0432.CCR-05-2225","volume":"12","author":"Hong","year":"2006","unstructured":"Hong K, Khwaja A, Liapi E et al (2006) New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12:2563\u20132567","journal-title":"Clin Cancer Res"},{"key":"2211_CR7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00686676","volume":"33","author":"Watanabe","year":"1994","unstructured":"Watanabe S, Nishioka M, Ohta Y et al (1994) Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular-carcinoma. Cancer Chemother Pharmacol 33:93\u201396","journal-title":"Cancer Chemother Pharmacol"},{"key":"2211_CR8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00687105","volume":"31","author":"Ichida","year":"1992","unstructured":"Ichida T, Kato M, Hayakawa A et al (1992) Treatment of hepatocellular carcinoma with a CDDP-epirubicin-lipiodol suspension \u2013 a pilot clinicopharmacological study. Cancer Chemother Pharmacol 31:51\u201359","journal-title":"Cancer Chemother Pharmacol"},{"key":"2211_CR9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/00000421-200012000-00006","volume":"23","author":"Ono","year":"2000","unstructured":"Ono Y, Yoshimasu T, Ashikaga R et al (2000) Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23:564\u2013568","journal-title":"Am J Clin Oncol"},{"key":"2211_CR10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00000421-199506000-00005","volume":"18","author":"Ikeda","year":"1995","unstructured":"Ikeda K, Saitoh S, Koida I et al (1995) A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 18:204\u2013210","journal-title":"Am J Clin Oncol"},{"key":"2211_CR11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000421-199704000-00021","volume":"20","author":"Ikeda","year":"1997","unstructured":"Ikeda K, Saitoh S, Suzuki Y et al (1997) A prospective randomized administration of 5\u2019-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 20:202\u2013208","journal-title":"Am J Clin Oncol"},{"key":"2211_CR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25\u201334","journal-title":"Lancet Oncol"},{"key":"2211_CR13","first-page":"168","volume":"64","author":"Detry","year":"2009","unstructured":"Detry O, Delwaide J, De Roover A et al (2009) Palliative management of hepatocarcinoma with sorafenib (nexavar). Results of the SHARP study (Sorafenib Hepato Carcinoma Assessment Randomized Protocol Rrial). Rev Med Liege 64:168\u2013170","journal-title":"Rev Med Liege"},{"key":"2211_CR14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0168-8278(91)90873-A","volume":"13","author":"Johnson","year":"1991","unstructured":"Johnson PJ, Kalayci C, Dobbs N et al (1991) Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular-carcinoma \u2013 effect of coadministration of lipiodol. J Hepatol 13:120\u2013127","journal-title":"J Hepatol"},{"key":"2211_CR15","first-page":"61","volume":"24","author":"Matsuo","year":"1997","unstructured":"Matsuo N, Uchida H, Sakaguchi H et al (1997) Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma: study based on lipiodol accumulation patterns and histopathologic findings. Semin Oncol 24:61\u201370","journal-title":"Semin Oncol"},{"key":"2211_CR16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1148\/radiographics.14.3.8066276","volume":"14","author":"Coldwell","year":"1994","unstructured":"Coldwell DM, Stokes KR, Yakes WF (1994) Embolotherapy \u2013 agents, clinical applications, and techniques. Radiographics 14:623\u2013643","journal-title":"Radiographics"},{"key":"2211_CR17","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/01.RVI.0000182160.26798.A2","volume":"16","author":"Brown","year":"2005","unstructured":"Brown DB, Pilgram TK, Darcy MD et al (2005) Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 16:1661\u20131666","journal-title":"J Vasc Interv Radiol"},{"key":"2211_CR18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1002\/cncr.21883","volume":"106","author":"Covey","year":"2006","unstructured":"Covey AM, Maluccio MA, Schubert J et al (2006) Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. Cancer 106:2181\u20132189","journal-title":"Cancer"},{"key":"2211_CR19","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00270-007-9268-2","volume":"31","author":"Stampfl","year":"2008","unstructured":"Stampfl S, Stampfl U, Bellemann N et al (2008) Biocompatibility and recanalization characteristics of hydrogel microspheres with polyzene-F as polymer coating. Cardiovasc Intervent Radiol 31:799\u2013806","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2211_CR20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00270-007-9280-6","volume":"31","author":"Kettenbach","year":"2008","unstructured":"Kettenbach J, Stadler A, Katzler IV et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31:468\u2013476","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2211_CR21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3348\/kjr.2008.9.6.534","volume":"9","author":"Ji","year":"2008","unstructured":"Ji SK, Cho YK, Ahn YS et al (2008) Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol 9:534\u2013540","journal-title":"Korean J Radiol"},{"key":"2211_CR22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1148\/radiology.163.2.3031724","volume":"163","author":"Takayasu","year":"1987","unstructured":"Takayasu K, Shima Y, Muramatsu Y et al (1987) Hepatocellular-carcinoma \u2013 treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 163:345\u2013351","journal-title":"Radiology"},{"key":"2211_CR23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00270-002-2524-6","volume":"26","author":"Geschwind","year":"2003","unstructured":"Geschwind JFH, Ramsey DE, Cleffken B et al (2003) Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 26:111\u2013117","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2211_CR24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF00687107","volume":"31","author":"Horiguchi","year":"1992","unstructured":"Horiguchi Y, Itoh M, Takagawa H et al (1992) Assessment of chemoembolization therapy for primary liver-cancer using a stabilized adriamycin-lipiodol suspension. Cancer Chemother Pharmacol 31:60\u201364","journal-title":"Cancer Chemother Pharmacol"},{"key":"2211_CR25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/BF02779132","volume":"17","author":"Monna","year":"1982","unstructured":"Monna T, Kanno T, Marumo T et al (1982) A comparison of transcatheter arterial embolization with one shot therapy for the patients with hepatic cell carcinoma. Gastroenterol Jpn 17:542\u2013549","journal-title":"Gastroenterol Jpn"},{"key":"2211_CR26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/BF00201780","volume":"18","author":"Yamashita","year":"1993","unstructured":"Yamashita Y, Torashima M, Oguni T et al (1993) Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation. Abdom Imaging 18:352\u2013356","journal-title":"Abdom Imaging"},{"key":"2211_CR27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/028418500127344966","volume":"41","author":"Tarazov","year":"2000","unstructured":"Tarazov PG, Polysalov VN, Prozorovskij KV et al (2000) Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol 41:156\u2013160","journal-title":"Acta Radiol"},{"key":"2211_CR28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1051-0443(07)61910-1","volume":"12","author":"Song","year":"2001","unstructured":"Song SY, Chung JW, Han JK et al (2001) Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 12:313\u2013320","journal-title":"J Vasc Interv Radiol"},{"key":"2211_CR29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004836-200105000-00013","volume":"32","author":"Kim","year":"2001","unstructured":"Kim HK, Chung YH, Song BC et al (2001) Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 32:423\u2013427","journal-title":"J Clin Gastroenterol"},{"key":"2211_CR30","first-page":"609","volume":"27","author":"Wang","year":"2005","unstructured":"Wang MQ, Shao RH, Ye HY et al (2005) Investigation of bile duct injury after transcatheter arterial chemoembolization. Zhonghua Zhong Liu Za Zhi 27:609\u2013612","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"2211_CR31","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/cncr.10407","volume":"94","author":"Chan","year":"2002","unstructured":"Chan AO, Yuen MF, Hui CK et al (2002) A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94:1747\u20131752","journal-title":"Cancer"},{"key":"2211_CR32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/j.gastro.2006.05.021","volume":"131","author":"Takayasu","year":"2006","unstructured":"Takayasu K, Arii S, Ikai I et al (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461\u2013469","journal-title":"Gastroenterology"},{"key":"2211_CR33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2008.01.022","volume":"48","author":"Llovet","year":"2008","unstructured":"Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):20\u201337","journal-title":"J Hepatol"},{"key":"2211_CR34","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1055\/s-2007-963285","volume":"179","author":"Vogl","year":"2007","unstructured":"Vogl TJ, Zangos S, Balzer JO et al (2007) Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results. Rofo 179:1113\u20131126","journal-title":"Rofo"},{"key":"2211_CR35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"Llovet","year":"2003","unstructured":"Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429\u2013442","journal-title":"Hepatology"},{"key":"2211_CR36","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1148\/radiology.195.3.7754005","volume":"195","author":"Hatanaka","year":"1995","unstructured":"Hatanaka Y, Yamashita Y, Takahashi M et al (1995) Unresectable hepatocellular-carcinoma \u2013 analysis of prognostic factors in transcatheter management. Radiology 195:747\u2013752","journal-title":"Radiology"},{"key":"2211_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00687096","volume":"31","author":"Kawai","year":"1992","unstructured":"Kawai S, Okamura J, Ogawa M et al (1992) Prospective and randomized clinical-trial for the treatment of hepatocellular-carcinoma \u2013 a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (1st cooperative study). Cancer Chemother Pharmacol 31:1\u20136","journal-title":"Cancer Chemother Pharmacol"},{"key":"2211_CR38","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/1097-0142(19941101)74:9<2449::AID-CNCR2820740910>3.0.CO;2-4","volume":"74","author":"Chang","year":"1994","unstructured":"Chang JM, Tzeng WS, Pan HB et al (1994) Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 74:2449\u20132453","journal-title":"Cancer"},{"key":"2211_CR39","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","volume":"33","author":"Malagari","year":"2010","unstructured":"Malagari K, Pomoni M, Kelekis A et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541\u2013551","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2211_CR40","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1440-1746.2007.04997.x","volume":"22","author":"Wu","year":"2007","unstructured":"Wu XZ, Xie GR, Chen D (2007) Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 22:1178\u20131182","journal-title":"J Gastroenterol Hepatol"},{"key":"2211_CR41","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","volume":"103","author":"Sergio","year":"2008","unstructured":"Sergio A, Cristofori C, Cardin R et al (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103:914\u2013921","journal-title":"Am J Gastroenterol"},{"key":"2211_CR42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1478-3231.1999.tb00005.x","volume":"19","author":"Kobayashi","year":"1999","unstructured":"Kobayashi N, Ishii M, Ueno Y et al (1999) Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver 19:25\u201331","journal-title":"Liver"},{"key":"2211_CR43","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jvir.2009.12.390","volume":"21","author":"Erinjeri","year":"2010","unstructured":"Erinjeri JP, Salhab HM, Covey AM et al (2010) Arterial patency after repeated hepatic artery bland particle embolization. J Vasc Interv Radiol 21:522\u2013526","journal-title":"J Vasc Interv Radiol"},{"key":"2211_CR44","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3171\/jns.1995.83.6.1029","volume":"83","author":"Siegal","year":"1995","unstructured":"Siegal T, Horowitz A, Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83:1029\u20131037","journal-title":"J Neurosurg"},{"key":"2211_CR45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/ncponc0512","volume":"3","author":"Hong","year":"2006","unstructured":"Hong K, Georgiades CS, Geschwind JFH (2006) Technology Insight: image-guided therapies for hepatocellular carcinoma \u2013 intra-arterial and ablative techniques. Nat Clin Pract Oncol 3:315\u2013324","journal-title":"Nat Clin Pract Oncol"},{"key":"2211_CR46","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s00270-010-0044-3","volume":"34","author":"Malagari","year":"2011","unstructured":"Malagari K, Pomoni M, Spyridopoulos TN et al (2011) Safety profile of sequential transcatheter chemoembolization with DC Bead: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol 34:774\u2013785","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2211_CR47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","volume":"33","author":"Lammer","year":"2010","unstructured":"Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41\u201352","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2211_CR48","doi-asserted-by":"crossref","unstructured":"Ten Haken RK, Lawrence TS, Dawson LA (2006) Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma: in regards to Xu et al. Int J Radiat Oncol Biol Phys 66:1272\u20131273 (Int J Radiat Oncol Biol Phys 2006;65:189\u2013195)","DOI":"10.1016\/j.ijrobp.2006.08.003"},{"key":"2211_CR49","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497\u2013507 e492","journal-title":"Gastroenterology"},{"key":"2211_CR50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.21980","volume":"47","author":"Kulik","year":"2008","unstructured":"Kulik LM, Carr BI, Mulcahy MF et al (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71\u201381","journal-title":"Hepatology"}],"container-title":["Der Radiologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-011-2211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00117-011-2211-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-011-2211-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T10:51:02Z","timestamp":1561200662000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00117-011-2211-1"}},"subtitle":["Ist Chemotherapie alles?"],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["2211"],"URL":"https:\/\/doi.org\/10.1007\/s00117-011-2211-1","relation":{},"ISSN":["0033-832X","1432-2102"],"issn-type":[{"value":"0033-832X","type":"print"},{"value":"1432-2102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}